EA201100322A8 - Интерферон и любой агент, индуцирующий ингибирование протеинфосфатазы 2а, например интерлейкин-1 и по выбору рибавирин, для лечения гепатитов b или c - Google Patents

Интерферон и любой агент, индуцирующий ингибирование протеинфосфатазы 2а, например интерлейкин-1 и по выбору рибавирин, для лечения гепатитов b или c

Info

Publication number
EA201100322A8
EA201100322A8 EA201100322A EA201100322A EA201100322A8 EA 201100322 A8 EA201100322 A8 EA 201100322A8 EA 201100322 A EA201100322 A EA 201100322A EA 201100322 A EA201100322 A EA 201100322A EA 201100322 A8 EA201100322 A8 EA 201100322A8
Authority
EA
Eurasian Patent Office
Prior art keywords
interleukin
factor
ribavirin
pharmaceutical composition
proteinphosphatase
Prior art date
Application number
EA201100322A
Other languages
English (en)
Other versions
EA022952B1 (ru
EA201100322A1 (ru
Inventor
Игорь Анатольевич Помыткин
Тамара Александровна ВИТКАЛОВА
Игорь Артурович Петропавлов
Original Assignee
Тамара Александровна ВИТКАЛОВА
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Тамара Александровна ВИТКАЛОВА filed Critical Тамара Александровна ВИТКАЛОВА
Publication of EA201100322A1 publication Critical patent/EA201100322A1/ru
Publication of EA201100322A8 publication Critical patent/EA201100322A8/ru
Publication of EA022952B1 publication Critical patent/EA022952B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2006—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses

Abstract

Настоящее изобретение относится к фармацевтическим комплектам, содержащим интерфероны в первом фармацевтическом составе, средства, вызывающие ингибирование протеинфосфатазы 2А (РР2А) во втором фармацевтическом составе, кроме того, содержащим рибавирин в третьем фармацевтическом составе, при этом средства, вызывающие ингибирование РР2А выбираются из группы, состоящей из инсулина, сенситайзеров инсулина, инсулиноподобного фактора роста-1, эпидермального фактора роста, фактора некроза опухолей, интерлейкина-1, интерлейкина-2, интерлейкина-3, интерлейкина-5, интерлейкина-6, интерлейкина-11, интерлейкина-12, интерлейкина-13, эритропоэтина, тромбопоэтина, гранулоцитарного колониестимулирующего фактора (G-CSF), гормона роста, пролактина, лептина, гранулоцитарно-моноцитарного колониестимулирующего фактора (GM-CSF), цилиарного нейротрофического фактора (CNTF), СТ-1, лейкоз ингибирующего фактора (LIF) и онкостатина М (OSM).
EA201100322A 2008-07-23 2008-07-23 Способ лечения вирусных гепатитов b и c EA022952B1 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2008/059643 WO2010009762A1 (en) 2008-07-23 2008-07-23 Interferon and an agent inducing inhibition of protein phosphatase 2a such as interleukin- 1 and optionally ribavirin for the treatment of hbv or hcv infection

Publications (3)

Publication Number Publication Date
EA201100322A1 EA201100322A1 (ru) 2011-10-31
EA201100322A8 true EA201100322A8 (ru) 2013-06-28
EA022952B1 EA022952B1 (ru) 2016-03-31

Family

ID=40996585

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201100322A EA022952B1 (ru) 2008-07-23 2008-07-23 Способ лечения вирусных гепатитов b и c

Country Status (3)

Country Link
EA (1) EA022952B1 (ru)
UA (1) UA106591C2 (ru)
WO (1) WO2010009762A1 (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2468815C1 (ru) * 2011-08-08 2012-12-10 Федеральное государственное бюджетное учреждение "Научный центр здоровья детей" Российской академии медицинских наук Способ повышения эффективности интерферонотерапии хронического гепатита с у детей
CN103071147A (zh) * 2011-10-26 2013-05-01 麦德托尼克公司 干扰素-α向乙型肝炎感染的患者的连续皮下施用
JP6853539B2 (ja) 2015-09-24 2021-03-31 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアＴｈｅ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃａｌｉｆｏｒｎｉａ 合成スフィンゴ脂質様分子、薬物、これらの合成方法、および処置方法
US20240066006A1 (en) * 2020-12-17 2024-02-29 The Regents Of The University Of California Antiviral Compounds and Applications Thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000507917A (ja) * 1995-11-02 2000-06-27 シェーリング コーポレイション 持続的低用量サイトカイン注入治療
GB9609932D0 (en) * 1996-05-13 1996-07-17 Hoffmann La Roche Use of IL-12 and IFN alpha for the treatment of infectious diseases
US20030147850A1 (en) * 2001-09-27 2003-08-07 Pomytkin Igor Anatolievich Composition and methods for potentiating therapeutic effects of interferons
WO2005071101A1 (en) * 2004-01-23 2005-08-04 University Hospital Of Basel Treatment of hepatitis c infection by increasing stat1 methylation
WO2006032711A1 (es) * 2004-08-18 2006-03-30 Instituto Científico Y Tecnológico De Navarra S.A. Uso del factor de crecimiento semejante a la insulina tipo i y de interferón alfa en el tratamiento de una enfermedad hepática crónica, kit y composiciones que los comprenden
ES2302402B1 (es) * 2005-06-16 2009-05-08 Proyecto De Biomedicina Cima, S.L. Uso de una citoquina de la familia de interleuquina-6 en la preparacion de una composicion para administracion combinada con interferon-alfa.

Also Published As

Publication number Publication date
EA022952B1 (ru) 2016-03-31
UA106591C2 (ru) 2014-09-25
EA201100322A1 (ru) 2011-10-31
WO2010009762A1 (en) 2010-01-28

Similar Documents

Publication Publication Date Title
EA201100322A8 (ru) Интерферон и любой агент, индуцирующий ингибирование протеинфосфатазы 2а, например интерлейкин-1 и по выбору рибавирин, для лечения гепатитов b или c
Stepkowski et al. STAT3: an important regulator of multiple cytokine functions
Chow et al. SnapShot: interferon signaling
Aman et al. Regulation of cytokine expression by interferon-alpha in human bone marrow stromal cells: inhibition of hematopoietic growth factors and induction of interleukin-1 receptor antagonist
CY1112200T1 (el) Συνδυασμοι για τη θεραπεια ασθενειων που ενεχουν κυτταρικο πολλαπλασιασμο
Kimura et al. Interleukin-1 beta (IL-1 beta) induces thrombocytosis in mice: possible implication of IL-6
Horowitz et al. Local regulators of bone: IL-1, TNF, lymphotoxin, interferon-γ, IL-8, IL-10, IL-4, the LIF/IL-6 family, and additional cytokines
Ertenli et al. Pathologic thrombopoiesis of rheumatoid arthritis
CA2522535A1 (en) Chemokine receptor binding heterocyclic compounds with enhanced efficacy
Talmadge The pharmaceutics and delivery of therapeutic polypeptides and proteins
Fehniger et al. Cutting edge: IL-15 costimulates the generalized Shwartzman reaction and innate immune IFN-γ production in vivo
JP2002524537A5 (ru)
JP2016537328A5 (ru)
JP2006517975A5 (ru)
Ramos et al. Chlorella vulgaris modulates immunomyelopoietic activity and enhances the resistance of tumor-bearing mice
MY149577A (en) Cytokine inhibitors
Hamblin Lymphokines and interleukins
WO2006134195A3 (es) Uso de una citoquina de la familia de interleuquina-6 en la preparación de una composición para administración combinada con interperón-alfa
WO2012177903A3 (en) Methods of treating cognitive impairment
WO2010017224A3 (en) Methods of treating cognitive impairment
WO1995009005B1 (en) Methods for stimulating interleukin-6 synthesis and inducing thrombocytopoiesis using oncostatin m
MX2020012478A (es) Metodos y composiciones para el tratamiento de la hipertension pulmonar.
JP2008546672A5 (ru)
EA200600021A1 (ru) Пиразолопиримидины
Lopes-Júnior et al. Emerging cytokine networks in osteosarcoma

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU